Brooklyn ImmunoTherapeutics, Inc.
Index- P/E- EPS (ttm)-2.10 Insider Own1.60% Shs Outstand58.80M Perf Week-18.04%
Market Cap19.93M Forward P/E- EPS next Y-0.53 Insider Trans0.00% Shs Float34.02M Perf Month-34.65%
Income-107.50M PEG- EPS next Q-0.14 Inst Own26.30% Short Float5.66% Perf Quarter-45.56%
Sales- P/S- EPS this Y6.50% Inst Trans-18.25% Short Ratio3.47 Perf Half Y-82.02%
Book/sh0.25 P/B1.35 EPS next Y0.00% ROA-323.00% Target Price3.00 Perf Year-97.14%
Cash/sh0.33 P/C1.03 EPS next 5Y20.00% ROE-609.10% 52W Range0.33 - 13.63 Perf YTD-91.89%
Dividend- P/FCF- EPS past 5Y1.60% ROI- 52W High-97.58% Beta4.61
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low0.95% ATR0.04
Employees10 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)23.51 Volatility12.02% 9.61%
OptionableYes Debt/Eq0.00 EPS Q/Q75.60% Profit Margin- Rel Volume1.48 Prev Close0.34
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume554.26K Price0.33
Recom2.00 SMA20-28.70% SMA50-36.71% SMA200-83.36% Volume172,869 Change-2.37%
Dec-29-21Initiated Cantor Fitzgerald Overweight $9
Oct-06-21Initiated Maxim Group Buy $20
Jul-26-22 09:49AM  
Jun-17-22 05:00PM  
Jun-07-22 07:30AM  
May-31-22 07:30AM  
May-27-22 04:30PM  
May-19-22 08:23AM  
Apr-21-22 07:30AM  
Apr-15-22 04:15PM  
Mar-09-22 04:15PM  
Mar-07-22 08:00AM  
Jan-27-22 05:38PM  
Jan-20-22 07:30AM  
Jan-13-22 08:30AM  
Dec-17-21 08:00AM  
Dec-14-21 08:47AM  
Dec-02-21 08:00AM  
Nov-29-21 08:00AM  
Nov-19-21 06:00AM  
Nov-09-21 04:35PM  
Oct-27-21 07:05AM  
Oct-14-21 04:15PM  
Oct-07-21 10:11PM  
Sep-23-21 04:30PM  
Sep-22-21 10:07AM  
Sep-21-21 08:30AM  
Sep-15-21 08:15AM  
Sep-13-21 08:00AM  
Sep-09-21 08:30AM  
Aug-20-21 04:15PM  
Aug-16-21 04:15PM  
Aug-13-21 02:22PM  
Jul-23-21 04:30PM  
Jul-19-21 08:00AM  
Jul-13-21 08:15AM  
Jul-12-21 08:15AM  
Jul-08-21 11:20AM  
Jul-06-21 05:57PM  
Jun-14-21 07:30AM  
Jun-09-21 07:30AM  
Jun-08-21 07:30AM  
Jun-02-21 08:00AM  
May-26-21 02:03PM  
May-24-21 02:58PM  
May-21-21 07:30AM  
May-18-21 07:30AM  
May-11-21 07:30AM  
May-07-21 07:30AM  
Apr-29-21 07:30AM  
Apr-26-21 07:30AM  
Apr-19-21 04:10PM  
Apr-15-21 04:10PM  
Apr-06-21 08:00AM  
Mar-25-21 05:20PM  
Dec-14-20 08:44AM  
Nov-04-20 06:05PM  
May-08-20 10:37PM  
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.